http://www.acc.org/Feed?clinicalTopicID=2db4bea0-4bbc-4fbd-b7b4-0e144f74ae32 Clinical Topic Feed: Nonstatins en /Latest-in-Cardiology/Articles/2026/05/19/15/49/JACC-Spotlight-Issue-2026-Dyslipidemia-Guideline A special JACC Spotlight Issue supporting the recently published 2026 ACC/AHA Guideline on the Management of Dyslipidemia, offers commentaries that provide a comprehensive overview of the new guideline recommendations and expert insights into understanding the science behind the recommendations... 1779206040000 Articles and Stories /Latest-in-Cardiology/Articles/2026/05/01/01/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1777637400000 Articles and Stories /Latest-in-Cardiology/Articles/2026/05/01/01/Journal-Wrap The hottest research from various peer-reviewed journals – handpicked weekly by the ACC. 1777637340000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/04/17/16/45/ApoB Appropriate Apolipoprotein B (apoB) may be used as a cost-effective marker to improve population health and guide lipid-lowering therapy (LLT) in primary prevention, according to a computer simulation study published April 8 in JAMA. 1776445740000 Articles and Stories /Latest-in-Cardiology/Articles/2026/04/01/01/Journal-Wrap The hottest research from various peer-reviewed journals – handpicked weekly by the ACC. 1775045400000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/mon-1045am-coralreef-acc-2026 The novel PCSK9 oral inhibitor enlicitide effectively lowered LDL-C in adults already being treated with statins, demonstrating a potential role as an add-on option for patients not meeting LDL-C goals, according to results from the CORALreef AddOn trial presented during an Investigative Horizons session at ACC.26 in New Orleans and simultaneously published in JACC. 1774885560000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-345pm-vesaliuscv-acc-2026 The PCSK9 inhibitor evolocumab reduced the risk of a first major cardiovascular event in patients with diabetes without known significant atherosclerosis, according to a prespecified subgroup analysis of the VESALIUS-CV trial, presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans and simultaneously published in JAMA. 1774730760000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/18/00/50/eagles-eye-view-18mar2025 In this week’s View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. 1773842400000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/13/15/20/ACC-AHA-Release-New-Clinical-Guideline-For-Managing-Dyslipidemia The new ACC/AHA Guideline on the Management of Dyslipidemia offers a comprehensive “one-stop shop” for addressing the evaluation, management and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a) (Lp[a]). 1773415860000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/12/10/54/Management-of-Checkpoint-Inhibitor-Myocarditis-in-the-CCU A 75-year-old man with a history of remote anterior ST-segment elevation myocardial infarction and stage IV malignant melanoma treated with combination immunotherapy (ipilimumab/nivolumab) presented to the oncology clinic with 3 days of exertional dyspnea and 24 hours of diplopia and neck weakness. 1773320700000 Articles and Stories